ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)
Prostate-specific membrane antigen
β Scribed by Fair, William R.; Israeli, Ron S.; Heston, Warren D.W.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 545 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
β¦ Synopsis
Background:
In an effort to discover new prostate-specific antigens (psas) to enhance our understanding of the functions and behavior of the prostate and the complex processes involved in prostate tumor progression, the structure and function of the psm antigen has been elucidated.
Methods:
The psm antigen was recognized using the 7e11-c5.3 monoclonal antibody, generated against the lncap human prostate adenocarcinoma cell line. the psm cdna was isolated by pcr, using tryptic peptides of immunoprecipitated psm to design degenerate primers.
Results:
The prostate specific membrane antigen (psm) is a 100 kd glycoprotein which appears to be a type ii integral membrane protein. the protein and cdna have been extensively characterized and the findings reviewed in the report.
Conclusions:
Psm, a new prostate antigen is valuable as a marker for hematogenous micro-metastatic tumor dissemination as detected in rt-pcr assays of peripheral blood. psm has many properties that may be potentially useful as a molecular target in monoclonal antibody directed strategies of tumor imaging and therapy.
π SIMILAR VOLUMES
## Abstract Despite recent advances, advanced prostate cancer is suboptimally responsive to current chemotherapeutic agents. Radiolabeled monoclonal antibody therapy that targets prostateβspecific membrane antigen (PSMA) shows promise and is an area of active investigation. J591 is a deimmunized Ig
## BACKGROUND. Two new prostate cancer markers, free-prostate specific antigen (f-PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two-year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.
Prostate-specific antigen (PSA) has revolutionized the diagnosis and management of men with prostate cancer. Significant advances have been made since the early development of immunoassays. While PSA is useful for staging and monitoring of established disease, it has shown the greatest utility in th
Previous studies have suggested that serum prostate-specific antigen (PSA) levels are under androgenic influence, especially in patients with adenocarcinoma of the prostate. PSMA (prostate-specific membrane antigen) is thought to reflect hormonal or clonal resistance or an independence with respect
Prostate-specific membrane antigen (PSMA) is a protein that is expressed predominantly in normal prostate epithelial cells and in most adenocarcinomas of the prostate (Cap) and in virtually all Cap metastases. In this article we describe the cloning of a 2-kb human genomic DNA fragment containing th